Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lazaro-Martinez, J.L.; Tardaguila-Garcia, A.; Garcia-Klepzig, J.L. Diagnostic and therapeutic update on diabetic foot osteomyelitis. Endocrinol. Diabetes Nutr. 2017, 64, 100–108. [Google Scholar] [CrossRef] [PubMed]
- Lazaro Martinez, J.L.; Garcia Alvarez, Y.; Tardaguila-Garcia, A.; Garcia Morales, E. Optimal management of diabetic foot osteomyelitis: Challenges and solutions. Diabetes Metab. Syndr. Obes. 2019, 12, 947–959. [Google Scholar] [CrossRef]
- Tardaguila-Garcia, A.; Sanz-Corbalan, I.; Garcia-Alamino, J.M.; Ahluwalia, R.; Uccioli, L.; Lazaro-Martinez, J.L. Medical Versus Surgical Treatment for the Management of Diabetic Foot Osteomyelitis: A Systematic Review. J. Clin. Med. 2021, 10, 1237. [Google Scholar] [CrossRef]
- Tardaguila-Garcia, A.; Garcia-Alvarez, Y.; Garcia-Morales, E.; Lopez-Moral, M.; Sanz-Corbalan, I.; Lazaro-Martinez, J.L. Long-Term Complications after Surgical or Medical Treatment of Predominantly Forefoot Diabetic Foot Osteomyelitis: 1 Year Follow. J. Clin. Med. 2021, 10, 1943. [Google Scholar] [CrossRef] [PubMed]
- Tardaguila-Garcia, A.; Sanz-Corbalan, I.; Lopez-Moral, M.; Garcia-Madrid, M.; Garcia-Morales, E.; Lazaro-Martinez, J.L. Are Digital Arthroplasty and Arthrodesis Useful and Safe Surgical Techniques for the Management of Patients with Diabetic Foot? Adv. Skin Wound Care. 2022, 35, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Tardaguila-Garcia, A.; Garcia Alvarez, Y.; Garcia-Morales, E.; Alvaro-Afonso, F.J.; Sanz-Corbalan, I.; Lazaro-Martinez, J.L. Utility of Blood Parameters to Detect Complications during Long-Term Follow-Up in Patients with Diabetic Foot Osteomyelitis. J. Clin. Med. 2020, 9, 3768. [Google Scholar] [CrossRef] [PubMed]
- Tardaguila-Garcia, A.; Garcia-Alvarez, Y.; Sanz-Corbalan, I.; Lopez-Moral, M.; Molines-Barroso, R.J.; Lazaro-Martinez, J.L. Could X-ray Predict Long-term Complications in Patients with Diabetic Foot Osteomyelitis? Adv. Skin Wound Care 2022, 35, 1–5. [Google Scholar] [CrossRef]
- Aragon-Sanchez, J.; Lipsky, B.A.; Lazaro-Martinez, J.L. Diagnosing diabetic foot osteomyelitis: Is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients? Diabet Med. 2011, 28, 191–194. [Google Scholar] [CrossRef]
- Lipsky, B.A.; Senneville, É.; Abbas, Z.G.; Aragón-Sánchez, J.; Diggle, M.; Embil, J.M.; Kono, S.; Lavery, L.A.; Malone, M.; van Asten, S.A.; et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes/Metab. Res. Rev. 2020, 36 (Suppl. S1), e3280. [Google Scholar] [CrossRef]
- Tardaguila-Garcia, A.; Sanz-Corbalan, I.; Garcia-Morales, E.; Garcia-Alvarez, Y.; Molines-Barroso, R.J.; Lazaro-Martinez, J.L. Diagnostic Accuracy of Bone Culture Versus Biopsy in Diabetic Foot Osteomyelitis. Adv. Skin Wound Care 2021, 34, 204–208. [Google Scholar] [CrossRef]
- Hinchliffe, R.J.; Forsythe, R.O.; Apelqvist, J.; Boyko, E.J.; Fitridge, R.; Hong, J.P.; Katsanos, K.; Mills, J.L.; Nikol, S.; Reekers, J.; et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes/Metabolism Res. Rev. 2020, 36, e3276. [Google Scholar] [CrossRef] [PubMed]
- Kalani, M.; Brismar, K.; Fagrell, B.; Ostergren, J.; Jorneskog, G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999, 22, 147–151. [Google Scholar] [CrossRef] [PubMed]
- Norgren, L.; Hiatt, W.R.; Dormandy, J.A.; Nehler, M.R.; Harris, K.A.; Fowkes, F.G.R. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 2007, 45, S5–S67. [Google Scholar] [CrossRef] [PubMed]
- Schaper, N.C.; van Netten, J.J.; Apelqvist, J.; Bus, S.A.; Hinchliffe, R.J.; Lipsky, B.A.; IWGDF Editorial Board. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab. Res. Rev. 2020, 36 (Suppl. S1), e3266. [Google Scholar] [CrossRef] [PubMed]
- Lipsky, B.A.; Berendt, A.R.; Cornia, P.B.; Pile, J.C.; Peters, E.J.; Armstrong, D.G.; Deery, H.G.; Embil, J.M.; Joseph, W.S.; Karchmer, A.W.; et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 2012, 54, e132–e173. [Google Scholar] [CrossRef]
- Lipsky, B.A. Treating diabetic foot osteomyelitis primarily with surgery or antibiotics: Have we answered the question? Diabetes Care 2014, 37, 593–595. [Google Scholar] [CrossRef]
- Aragon-Sanchez, J. Treatment of diabetic foot osteomyelitis: A surgical critique. Int. J. Low. Extremity Wounds 2010, 9, 37–59. [Google Scholar] [CrossRef]
- Tardaguila-Garcia, A.; Lazaro-Martinez, J.L.; Sanz-Corbalan, I.; Garcia-Alvarez, Y.; Alvaro-Afonso, F.J.; Garcia-Morales, E. Correlation between Empirical Antibiotic Therapy and Bone Culture Results in Patients with Osteomyelitis. Adv. Ski. Wound Care 2019, 32, 41–44. [Google Scholar] [CrossRef]
- Tone, A.; Nguyen, S.; Devemy, F.; Topolinski, H.; Valette, M.; Cazaubiel, M.; Fayard, A.; Beltrand, É.; Lemaire, C.; Senneville, É. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: A multicenter open-label controlled randomised study. Diabetes Care 2015, 38, 302–307. [Google Scholar] [CrossRef]
- van Netten, J.J.; Bus, S.A.; Apelqvist, J.; Lipsky, B.A.; Hinchliffe, R.J.; Game, F.; Rayman, G.; Lazzarini, P.A.; Forsythe, R.O.; Peters, E.J.; et al. Definitions and criteria for diabetic foot disease. Diabetes/Metabolism Res. Rev. 2020, 36, e3268. [Google Scholar] [CrossRef]
- Rayman, G.; Vas, P.; Dhatariya, K.; Driver, V.; Hartemann, A.; Londahl, M.; Piaggesi, A.; Apelqvist, J.; Attinger, C.; Game, F.; et al. Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update). Diabetes/Metabolism Res. Rev. 2020, 36, e3283. [Google Scholar] [CrossRef] [PubMed]
- General Assembly of the World Medical, A. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J. Am. Coll. Dent. 2014, 81, 14–18. [Google Scholar]
- Tardaguila-Garcia, A.; Garcia-Alvarez, Y.; Sanz-Corbalan, I.; Alvaro-Afonso, F.J.; Molines-Barroso, R.J.; Lazaro-Martinez, J.L. Role of inflammatory markers in the healing time of diabetic foot osteomyelitis treated by surgery or antibiotics. J. Wound Care 2020, 29, 5–10. [Google Scholar] [CrossRef] [PubMed]
- van Asten, S.A.; Jupiter, D.C.; Mithani, M.; La Fontaine, J.; Davis, K.E.; Lavery, L.A. Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int. Wound J. 2017, 14, 142–148. [Google Scholar] [CrossRef]
- Lazaro-Martinez, J.L.; Aragon-Sanchez, J.; Garcia-Morales, E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: A randomized comparative trial. Diabetes Care 2014, 37, 789–795. [Google Scholar] [CrossRef] [PubMed]
Variables | n = 116 |
---|---|
Male/female, n (%) | 96 (82.2)/20 (17.2) |
Age (years), mean ± SD | 62.9 ± 10.1 |
DM (years), mean ± SD | 17.5 ± 12.3 |
DM type 1/type 2, n (%) | 12 (10.3)/104 (89.7) |
Body mass index (Kg/m2), mean ± SD | 28.3 ± 5.5 |
HbA1c (%), mean ± SD | 8.1 ± 6.0 |
Neuropathy, n (%) | 116 (100.0) |
Affected superficial sensitivity, n (%) | 116 (100.0) |
Affected deep sensitivity, n (%) | 116 (100.0) |
PAD, n (%) | 48 (41.4) |
ABI; mean ± SD | 1.0 ± 0.3 |
TBI; mean ± SD | 0.7 ± 0.2 |
TcPO2; mean ± SD | 34.1 ± 13.9 |
Duration from ulcer (weeks), mean ± SD | 15.7 ± 32.1 |
Location of ulcer: forefoot/midfoot/hindfoot, n (%) | 107 (92.2)/5 (4.3)/4 (3.4) |
Presence of clinical signs of infection, n (%) | 72 (62.1) |
Radiological signs in X-ray: focal loss of trabecular pattern or marrow radiolucency (demineralisation)/periosteal reaction or elevation/sequestrum/loss of bone cortex, with bony erosion or demineralisation/another type of signs, n (%) | 34 (29.3)/36 (31)/12 (10.3)/26 (22.4)/8 (7) |
Blood parameters: leukocytes (×109/L)/neutrophils (×109/L)/lymphocytes (×109/L)/monocytes (×109/L)/eosinophils (×109/L)/basophils (×109/L)/ESR (mm/h)/glycaemia (mmol/L)/CRP) (nmol/L)/alkaline phosphatase (UI/L)/albumin (g/L)/creatinine (mg/dl), mean ± SD | 8.7 ± 2.5/5.6 ± 2.3/2.1 ± 0.9/0.7 ± 0.5/0.3 ± 0.2/0.04 ± 0.04/34.3 ± 28.4/8.45 ± 3.16/99.6 ± 46.5/40 ± 6/1.6 ± 1.7 |
Surgical treatment/medical treatment | 96 (82.2)/20 (17.2) |
Variables | Mean (weeks) | IQR (weeks) | p-Value |
---|---|---|---|
Elevated leukocytes | 13 | 9–21 | 0.761 |
Normalised leukocytes | 13 | 8–22 | |
Elevated neutrophils | 18 | 12–22 | 0.117 |
Normalised neutrophils | 12 | 8–20 | |
Elevated lymphocytes | 8 | 7.5–8.5 | 0.057 |
Normalised lymphocytes | 13 | 8–22 | |
Elevated monocytes | 12 | 6–20 | 0.557 |
Normalised monocytes | 13 | 8–22 | |
Elevated eosinophils | 35 | 23–35 | 0.004 |
Normalised eosinophils | 13 | 8–20 | |
Elevated ESR | 13 | 9–21 | 0.378 |
Normalised ESR | 12 | 8–22 | |
Elevated glycaemia | 12 | 8–22 | 0.831 |
Normalised glycaemia | 14 | 8.5–20 | |
Elevated HbA1c | 13 | 8–22 | 0.716 |
Normalised HbA1c | 16 | 8–20 | |
Elevated CRP | 13 | 8–22 | 0.278 |
Normalised CRP | 12 | 8–20 | |
Elevated alkaline phosphatase | 19 | 12–23 | 0.096 |
Normalised alkaline phosphatase | 13 | 8–20 | |
Elevated albumin | 11 | 10–12 | 0.634 |
Normalised albumin | 13 | 8–22 | |
Elevated creatinine | 12 | 8–23.5 | 0.972 |
Normalised creatinine | 13 | 8.5–20 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tardáguila-García, A.; Álvaro-Afonso, F.J.; García-Madrid, M.; López-Moral, M.; Sanz-Corbalán, I.; Lázaro-Martínez, J.L. Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis. J. Clin. Med. 2023, 12, 345. https://doi.org/10.3390/jcm12010345
Tardáguila-García A, Álvaro-Afonso FJ, García-Madrid M, López-Moral M, Sanz-Corbalán I, Lázaro-Martínez JL. Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis. Journal of Clinical Medicine. 2023; 12(1):345. https://doi.org/10.3390/jcm12010345
Chicago/Turabian StyleTardáguila-García, Aroa, Francisco Javier Álvaro-Afonso, Marta García-Madrid, Mateo López-Moral, Irene Sanz-Corbalán, and José Luis Lázaro-Martínez. 2023. "Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis" Journal of Clinical Medicine 12, no. 1: 345. https://doi.org/10.3390/jcm12010345
APA StyleTardáguila-García, A., Álvaro-Afonso, F. J., García-Madrid, M., López-Moral, M., Sanz-Corbalán, I., & Lázaro-Martínez, J. L. (2023). Variables That Could Influence Healing Time in Patients with Diabetic Foot Osteomyelitis. Journal of Clinical Medicine, 12(1), 345. https://doi.org/10.3390/jcm12010345